Archive
The National Cancer Institute periodically highlights a particular trial or group of trials out of more than 150 available cancer clinical trials conducted at the National Institutes of Health in Bethesda, Maryland. Below you will find the archived list of previous Clinical Trial Spotlights:
Archived Clinical Trial Spotlights
Clinical Trial—Dr. Frank Balis
- Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Cancer
NCI-07-C-0189
Clinical Trials—Dr. Michael Bishop
- Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
NCI-07-C-0195 - Adoptive Cell Therapy for B-Cell Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation With Costimulated, Tumor-Derived Lymphocytes
NCI-07-C-0064 - Phase I Trial of T Cell Exchange With Th2/Tc2 Cells for Allogenic Stem Cell Transplantation After Reduced Intensity Conditioning for Metastatic Breast Cancer
NCI-04-C-0131 - T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors for Hematologic Malignancies
NCI-04-C-0116
Clinical Trials—Dr. Kevin Camphausen
- A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination With Temodar and Radiation Therapy in Patients With High Grade Gliomas
NCI-06-C-0112 - Urinary and Serum VEGF and MMP Levels for Radiation Therapy in Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
NCI-04-C-0200
Clinical Trials—Deborah Citrin
- A Phase II Study of Hypofractionated Highly Conformal Radiation With Helical Tomotherapy for Extra-Cranial Oligometastases
NCI-07-C-0230 - A Pilot Study of Markers of Tumor Burden and Radiation Toxicity in the Blood, Urine, and Stool of Patients Receiving Radiotherapy for Gastrointestinal Malignancies
NCI-07-C-0111
Clinical Trial—Dr. William Dahut
- A Phase II Study of Docetaxel, Thalidomide, Prednisone, and Bevacizumab in Patients With Metastatic Androgen-Independent Prostate Cancer
NCI-04-C-0257
Clinical Trials—Dr. Phillip Dennis
- A Phase I/II Trial of Pemetrexed (Alimta®) Combined With Sirolimus (Rapamycin, Rapamune®) in Subjects With Relapsed or Refractory NSCLC Whose Tumors Bear Activation of mTOR
NCI-08-C-0078 - A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
NCI-07-C-0047
Clinical Trial—Dr. James Doroshow
- A Phase I Trial of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine in Advanced Malignancies
NCI-06-C-0221
Clinical Trial—Dr. Kieron Dunleavy
- A Phase I/II Study of Flavopiridol in Relapsed or Refractory Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
NCI-07-C-0081
Clinical Trials—Dr. Howard Fine
- A Phase II Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas
NCI-08-C-0101 - A Phase II Trial of Enzastaurin (LY317615) in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas
NCI-08-C-0015 - A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas
NCI-07-C-0053 - Phase II Trial of Bevacizumab for Patients With Recurrent High-Grade Gliomas
NCI-06-C-0064 - Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas
NCI-06-C-0063 - A Phase II Trial of Tamoxifen and Bortezomib in Patients With Recurrent High-Grade Gliomas
NCI-05-C-0137 - A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative
NCI-02-C-0140 - Evaluation of the Natural History of Patients With Tumors of the Central Nervous System
NCI-01-C-0070
Clinical Trial—Dr. Daniel Fowler
- Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055
Clinical Trials—Dr. Elizabeth Fox
- A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors
NCI-07-C-0054 - Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia
NCI-06-C-0152
Clinical Trial—Dr. Ronald Gress
- Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic Stem Cell Transplantation in Children and Adults
NCI-08-C-0097
Clinical Trials—Dr. James Gulley
- A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation
NCI-07-C-0188 - A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer
NCI-07-C-0107 - A Randomized Phase 2.5 Study of 153Sm-EDTMP (Quadramet) With or Without a PSA TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer
NCI-07-C-0106 - A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination With PANVAC -V (vaccinia) and PANVAC-F (fowlpox) in Patients With Metastatic Breast Cancer
NCI-05-C-0229
Clinical Trial—Dr. Raffit Hassan
- Phase I, Single Center, Dose-Escalation Study of SS1(dsFv)-PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma
NCI-08-C-0026
Clinical Trials—Dr. John Janik
- Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia
NCI-06-C-0177 - Phase II Study of the Efficacy and Toxicity of Ontak® (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
NCI-05-C-0185 - A Pilot Study of MDX-CTLA-4 in Lymphoma
NCI-02-C-0284
Clinical Trials—Dr. Aradhana Kaushal
- Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation With Intensity Modulated Radiation Therapy (IMRT)
NCI-05-C-0241 - Phase I Study of Image Guided Dose Escalation With Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer
NCI-05-C-0191
Clinical Trials—Dr. Elise Kohn
- A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
NCI-07-C-0058 - A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
NCI-04-C-0232
Clinical Trial—Dr. Teri Kreisl
Clinical Trials—Dr. Robert Kreitman
- Phase II Study of LMB-2 Immunotoxin in Patients With Recurrent or Refractory CD25-Positive Hairy Cell Leukemia
NCI-06-C-0150 - A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas
NCI-04-C-0142 - Phase II Study of LMB-2 Immunotoxin in Patients With CD25-Positive Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCI-04-C-0121 - Phase II Trial of BL22 Immunotoxin in Hairy Cell Leukemia
NCI-04-C-0014
Clinical Trials—Dr. Shivaani Kummar
- A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux®) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
NCI-06-C-0164 - A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1alpha
NCI-05-C-0186
Clinical Trials—Dr. W. Marston Linehan
- A Phase II Study of ZD6474 (Vandetanib) in Subjects With Advanced Clear Cell Renal Carcinoma
NCI-08-C-0039 - Phase II Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients With von Hippel-Lindau Disease and Renal Tumors
NCI-04-C-0238
Clinical Trials—Dr. John Morris
- A Phase I Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-beta (TGF-ß) Monoclonal Antibody in Patients With Advanced Renal Cell Carcinoma or Malignant Melanoma
NCI-06-C-0200 - A Phase I Open-Label Single-Dose Study of Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R{beta} Subunit (CD122) in T-Cell Large Granular Lymphocytic Leukemia
NCI-04-C-0089 - A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer
NCI-04-C-0049 - Phase II Study of the Efficacy and Toxicity of CAMPATH-1H in the Therapy of Adult T-Cell Leukemia
NCI-03-C-0194 - Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia
NCI-00-C-0030
Clinical Trial—Dr. Steven Pavletic
- Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD)
NCI-04-C-0281
Clinical Trial—Dr. Richard Piekarz
- Phase I Trial of Romidepsin (Depsipeptide) Given on Days One, Three and Five in Patients With Thyroid and Other Advanced Cancers
NCI-03-C-0030
Clinical Trials—Dr. Steven Rosenberg
- Phase II Study of Metastatic Melanoma Using Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 F5 TCR-Gene Engineered Lymphocytes
NCI-07-C-0175 - Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma
NCI-06-C-0069
Clinical Trial—Dr. Claude Sportès
- A Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients With Metastatic Breast Cancer Untreated With Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion
NCI-03-C-0040
Clinical Trial—Dr. Ramaprasad Srinivasan
- A Phase II Study of the c-Met RTK Inhibitor GSK 1363089 (Formerly XL880) in Subjects With Papillary Renal-Cell Carcinoma (PRC)
NCI-07-C-0121
Clinical Trials—Dr. Katherine Warren
- Comparative Trial of Pediatric CNS Tumor Activity as Assessed by PET Imaging and Proton Magnetic Resonance Spectroscopy Imaging (MRSI)
NCI-03-C-0278 - Phase II Study of Pegylated Interferon Alfa-2b (PEG-Intron) in Children With Diffuse Pontine Gliomas
NCI-02-C-0193
Clinical Trials—Dr. Brigitte Widemann
- Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors
NCI-06-C-0043 - Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias
NCI-02-C-0031
Clinical Trials—Dr. Wyndham Wilson
- A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCI-07-C-0006 - Phase III Randomized Study of R-CHOP Versus Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
NCI-05-C-0252 - Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
NCI-05-C-0170 - Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas
NCI-04-C-0173 - Pilot Trial of Alemtuzumab and Dose-Adjusted EPOCH In Chemotherapy Naive Aggressive T and NK-Cell Lymphomas
NCI-03-C-0304 - Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
NCI-01-C-0030 - Treatment of Chronic Lymphocytic Leukemia: DNA Microarray Gene Expression Analysis
NCI-97-C-0178 - Treatment and Natural History Study of Lymphomatoid Granulomatosis
NCI-94-C-0074 - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma
NCI-93-C-0133
Clinical Trials—Dr. Robert Yarchoan
- A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede Development of Antiretroviral Resistance
NCI-06-C-0211 - Phase I and Pharmacokinetic Study of BAY 43-9006 Sorafenib) in Patients With Kaposi's Sarcoma
NCI-06-C-0083 - AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy
NCI-06-C-0051 - Pilot Study of Antiretroviral Therapy With or Without Bortezomib or Combination Chemotherapy and Rituximab or Observation Only in Treating Patients With Castleman's Disease
NCI-04-C-0275
Back to Top
